James Healy - Sep 27, 2021 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Director
Signature
/s/ Nathalie Auber, as Attorney in Fact for James I. Healy, M.D., Ph.D.
Stock symbol
CHRS
Transactions as of
Sep 27, 2021
Transactions value $
-$7,250,063
Form type
4
Date filed
9/29/2021, 08:18 PM
Previous filing
Jul 26, 2021
Next filing
Jan 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock, $0.0001 par value Sale -$1.81M -100K -23.05% $18.06 334K Sep 27, 2021 See Footnote F1, F2
transaction CHRS Common Stock, $0.0001 par value Sale -$830K -48.3K -14.45% $17.17 286K Sep 28, 2021 See Footnote F2, F3
transaction CHRS Common Stock, $0.0001 par value Sale -$4.61M -286K -100% $16.12 0 Sep 29, 2021 See Footnote F2, F4
holding CHRS Common Stock, $0.0001 par value 70.1K Sep 27, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
F2 The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.43, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.905, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.